Surgical Science Q1 2023: Outperformers tend to keep outperforming - Redeye

Redeye updates its estimates following Surgical Science’s Q1 2023 report, which took our forecasts to the woodshed. Educational Products sales came in c35% above our estimate. The company posted strong EBITDA and EBIT margins; both c2%-points higher than we anticipated. We believe that growth will moderate in the future while margin expansion continues. We raise our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/908820/surgical-science-q1-2023-outperformers-tend-to-keep-outperforming?utm_source=finwire&utm_medium=RSS